What it sells
Cancer Diagnosis 10X faster, 10X cheaper
Business model breakdown
Buyer: who owns the budget?
UnverifiedLab directors/pathologists buying an on-site DNA+RNA NGS workflow; biopharma clinical teams for trial profiling.
Trigger: what makes them buy now?
Shipping samples to reference labs delays results; labs want in-house NGS validated in under two months with MolDX submission support.
Workflow: what inputs become what output?
One prep for DNA and RNA, overnight sequencing on-site, report next day in Duoseq Suite with EPIC/EHR integration; under 10 minutes of technician time on lab robotics.
Economics: what it saves and how it charges
Claims 10x cheaper and 10x faster cancer genomics (sample to report in 2 days); likely sells assay/kit plus software and services to labs and biopharma.
Distribution: how it reaches customers
Contact-us led direct sales to labs, plus biopharma partnerships with custom trial portals and regulatory/biomarker support.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.